IP Library Granted Patent US 8,435,526
Granted Patent B2
US 8,435,526 · App. 13/452,026 · Granted May 7, 2013

Methods of treating mucositis using anti-TNF antibodies

Inventor: Barbara S. Fox (Wayland, MA)
Assignee: Avaxia Biologies, Incorporated
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,435,526
App. No.
13/452,026
Granted
May 7, 2013
Kind
B2
Abstract

In accordance with the invention, the development and use of antibodies within the digestive tract is provided. Antibodies are described that are used to treat disorders associated with altered permeability of the digestive tract. Antibodies are described with increased stability within the environment of the digestive tract. Antibodies are described with enhanced permeability to a compromised digestive tract.

Claims (10)

1. A method of treating mucositis in a patient comprising administering to the patient a therapeutically effective amount of a composition comprising an antibody specific for tumor necrosis factor (TNF) wherein the composition is administered topically to the digestive tract.

2. The method of claim 1 , wherein the composition comprises a polyclonal antibody.

3. The method of claim 1 , wherein the composition is administered topically to the oral cavity for treatment of oral or esophageal mucositis.

4. The method of claim 1 , wherein the composition is administered orally for treatment of intestinal mucositis.

5. The method of claim 1 , wherein the composition is administered orally in a dosage form suitable for oral administration to the gastrointestinal tract (GI).

6. The method of claim 1 , wherein the composition is administered rectally for treatment of intestinal mucositis.

7. The method of claim 1 , wherein the composition comprises a polyclonal antibody derived from milk or colostrum.

8. The method of claim 1 , wherein the mucositis is oral mucositis, esophageal mucositis or intestinal mucositis.

9. The method of claim 1 , wherein the mucositis is caused by radiation therapy.

10. The method of claim 1 , wherein the mucositis is caused by exposure to radiation outside of the context of radiation therapy.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2016
From: PMCM2, LLC
To: CIRCLE 33, LLC
Reel/Frame 038655/0771 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2016
From: AVAXIA BIOLOGICS, INC
To: PMCM2, LLC
Reel/Frame 038642/0709 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2013
From: FOX, BARBARA S.
To: AVAXIA BIOLOGICS, INCORPORATED
Reel/Frame 030440/0414 →
Continuity (6)
Division 12753438 · Apr 2, 2010
Continuation PCTUS2008078543 · Oct 2, 2008
Provisional Application 60976876 · Oct 2, 2007
Provisional Application 61015507 · Dec 20, 2007
Provisional Application 61055215 · May 22, 2008
Related Publication 20120315280A1 · Dec 13, 2012